Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: insights from the ARISTOPHANES study. Keshishian A. S Deitelzweig, A Keshishian, A Kang… - Journal of Clinical …, 2020 - mdpi.com GSID: leAvqjs60GYJ
Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. [No authors listed] OS Costa, J Beyer-Westendorf, V Ashton… - Current Medical …, 2020 - Taylor & Francis GSID: hPKAx6wJzgMJ
Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population. [No authors listed] JS Berger, F Laliberté, A Kharat, D Lejeune… - Current Medical …, 2021 - Taylor & Francis GSID: WZ2WgjEQ0RwJ
Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Weighing≥ 120 Kilograms versus 60–120 Kilograms. [No authors listed] EE Wiethorn, CM Bell, BS Wiggins - American Journal of Cardiovascular …, 2021 - Springer GSID: rGs-_jNmIxMJ
Non-vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation and (morbid) obesity or low body weight: a systematic review …. [No authors listed] M Grymonprez, TL De Backer, S Steurbaut… - … Drugs and Therapy, 2021 - Springer GSID: xrONna3Hd1wJ
